Compare Mesoblast Limited (MESO) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MPLX LP — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while MPLX LP trades at $56.3 (market cap $58.11B). The key difference: MPLX LP is far larger — about 33.2× Mesoblast Limited's market cap, and MPLX LP pays a 7.51% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MPLX | |
|---|---|---|
Market Cap | $1.75B | $58.11B |
Volume | 239,027 | 687,483 |
Sector | Health | Energy |
52-Week High | $20.96 | $60.51 |
52-Week Low | $13.19 | $47.80 |
Typical Hold Time | 15 Days | — |
Enterprise Value | $1.83B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
MPLX trades at $57.32, up 0.47% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, supported by $4.91B net income in 2025. Recent earnings show mixed results with a Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 11.3% upside potential.
The investment case balances strong cash flow generation and dividend stability against energy market volatility risks. MPLX's fee-based midstream model provides revenue resilience, though technical indicators suggest near-term pressure. The 67.86% buy rating consensus indicates Wall Street confidence in the company's ability to maintain distribution growth despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
